FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to the pharmaceutical industry, more specifically to a method of producing a composition containing nanoparticles of abiraterone acetate, and to a method for preparing a solid oral composition based thereon. Also disclosed is a pharmaceutical composition and a solid oral pharmaceutical composition containing: abaraterone acetate; ground grinding material; grinding agent selected from colloidal silica, surfactant, polymer, stearic acid and derivatives thereof; an antioxidant selected from ascorbic acid, butylated hydroxyanisole and butylated hydroxytoluene; and a binding agent selected from fumaric, tartaric and citric acids, where [D90] of the particles of abiraterone acetate is more than 100 nm and less than 1000 nm. Also disclosed are embodiments of a method of treating castration-resistant prostate cancer.
EFFECT: group of inventions provides improved profile of dissolving abiraterone acetate, as well as high stability of composition based on it by reducing oxidative degradation of active agent.
13 cl, 7 ex, 4 tbl, 8 dwg
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2589842C2 |
PERORAL COMPOSITIONS CONTAINING ESTER 17- HYDROXYPROHESTERON, AND CORRESPONDING METHODS | 2012 |
|
RU2640912C2 |
INHALATION PHARMACEUTICAL COMPOSITIONS | 2013 |
|
RU2697862C2 |
METHODOLOGY PREPARATIONS | 2014 |
|
RU2684914C2 |
MICROEMULSION COMPOSITIONS | 2019 |
|
RU2787998C1 |
SUPERCRITICAL LIQUID EXTRACT CONTAINING CARDIAC GLYCOSIDE | 2006 |
|
RU2398591C2 |
PRO-MEDICATION COMPOSITION FOR STRUGGLE AGAINST HEPAPATITIS C VIRUS | 2006 |
|
RU2435592C2 |
DRUG DELIVERY COMPOSITION | 2010 |
|
RU2589823C2 |
PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
PESTICIDE COMPOSITION CONTAINING ELEMENTAL SULFUR AND CHOLINE SALT OF PELARGONIC ACID | 2021 |
|
RU2812849C1 |
Authors
Dates
2020-09-11—Published
2014-03-17—Filed